Discounted Cash Flow (DCF) Analysis Levered

ADMA Biologics, Inc. (ADMA)

$5.26

-0.01 (0.00%)
All numbers are in Millions, Currency in USD
Stock DCF: -435.70 | 5.26 | overvalue

Free Cash Flow

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 16.9929.3542.2280.94154.08269.15470.14821.251,434.552,505.87
Revenue (%)
Operating Cash Flow -62.68-76.19-102-112.37-59.51-563.96-985.12-1,720.80-3,005.89-5,250.67
Operating Cash Flow (%)
Capital Expenditure -2.10-3.81-12.73-13.51-13.91-43.70-76.34-133.35-232.94-406.91
Capital Expenditure (%)
Free Cash Flow -64.77-80.01-114.73-125.88-73.42-607.66-1,061.46-1,854.15-3,238.83-5,657.58

Weighted Average Cost Of Capital

Share price $ 5.26
Beta 0.473
Diluted Shares Outstanding 197.87
Cost of Debt
Tax Rate -29.25
After-tax Cost of Debt 12.48%
Risk-Free Rate
Market Risk Premium
Cost of Equity 6.518
Total Debt 154.44
Total Equity 1,040.82
Total Capital 1,195.26
Debt Weighting 12.92
Equity Weighting 87.08
Wacc

Build Up Free Cash Flow

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 16.9929.3542.2280.94154.08269.15470.14821.251,434.552,505.87
Operating Cash Flow -62.68-76.19-102-112.37-59.51-563.96-985.12-1,720.80-3,005.89-5,250.67
Capital Expenditure -2.10-3.81-12.73-13.51-13.91-43.70-76.34-133.35-232.94-406.91
Free Cash Flow -64.77-80.01-114.73-125.88-73.42-607.66-1,061.46-1,854.15-3,238.83-5,657.58
WACC
PV LFCF -566.37-922.11-1,501.30-2,444.28-3,979.55
SUM PV LFCF -9,413.62

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 7.29
Free cash flow (t + 1) -5,770.73
Terminal Value -109,087.54
Present Value of Terminal Value -76,732.43

Intrinsic Value

Enterprise Value -86,146.05
Net Debt 67.92
Equity Value -86,213.97
Shares Outstanding 197.87
Equity Value Per Share -435.70